The goal of the Krantz Family Center for Cancer Research Awards is to support Krantz Center faculty in developing highly impactful cancer research projects. The Krantz Awards are expected to drive discovery, bolster cancer research across the institution, and produce a fundamental change in the understanding and treatment of cancer for patients around the world.
The Krantz Awards recognize varying degrees of progress and encourage collaboration across platforms. The number of awards within each category will be determined based on the quality, impact, and promise of individual projects.
Krantz Awards
Quantum Awards - Major initiative poised to have definitive impact on fundamental cancer research, diagnostics, or therapeutics. Quantum Awards may provide up to $1 million per year for two years, with the possibility to extend to a third year upon review of progress. These awards fund projects that have established proof-of-principle based on promising initial findings, are appropriate for rapid expansion, and have the potential to transform our understanding and treatment of cancer.
Breakthrough Awards - Transformative project based on research findings poised for expansion and scale. Breakthrough Awards may provide up to $500,000 per year for two years. These awards support new and innovative ideas to the point of proof-of-principle based on promising initial findings.
Spark Awards - Exploratory research with potential to yield major initiative. Spark Awards may provide up to $100,000 per year for one year to test exciting new thought-provoking ideas to the point of proof-of-principle.
Krantz Awards Announcement Status
The Krantz Family Center for Cancer Research will issue a Request for Applications among its faculty biannually. The amount of funding distributed at each of these two cycles will be at the discretion of the Review Committee, reflecting the quality of applications. The Review Committee is comprised of senior leaders in the Krantz Family Center for Cancer Research with representation from clinical investigators in the Mass General Cancer Center. The funded projects will be presented annually to the Krantz Family Center for Cancer Research Scientific Advisory Board.
The proposal submission period for the 2023 Krantz Awards is now closed. The Krantz Awards review committee has started meeting and is thoughtfully evaluating all submissions. Due to the volume of outstanding proposals, the selection process will take some time. The review committee aims to send out a first round of notifications mid-fall 2023 and choose final award winners by late fall, with the potential to start funding in early winter.
Review Committee Members
Internal Review Committee
Daniel Haber, MD, PhD Director, Krantz Family Center for Cancer Research Director, Mass General Cancer Center Kurt J. Isselbacher Professor of Oncology (Medicine) Investigator, Howard Hughes Medical Institute
Raul Mostoslavsky, PhD Scientific Director, Krantz Family Center for Cancer Research Laurel Schwartz Professor of Oncology (Medicine) Professor of Medicine, Harvard Medical School
Nir Hacohen, PhD Director, Center for Cancer Immunology, Krantz Family Center for Cancer Research Director, Center for Cell Circuits, Broad Institute of Harvard and MIT David P. Ryan Endowed Chair in Cancer Research Professor of Medicine, Harvard Medical School
Andrea McClatchey, PhD Director for Academic Affairs, Krantz Family Center for Cancer Research Poitras Family Endowed Chair in Cancer Research Professor of Pathology, Harvard Medical School
David Ryan, MD Clinical Director, Mass General Cancer Center Chief of Hematology-Oncology, Mass General Cancer Center Professor of Medicine, Harvard Medical School
Rebecca Heist, MD, MPH Associate Director for Clinical Research, Mass General Cancer Center Lee Albright and Nile Albright, MD Endowed Chair in Clinical Cancer Research Associate Professor of Medicine, Harvard Medical School
Keith Flaherty, MD Director of Clinical Research, Mass General Cancer Center Professor of Medicine, Harvard Medical School
External Scientific Advisory Board
External Advisory Board 2023
Dafna Bar-Sagi, PhD Saul J. Farber Professor in the Department of Biochemistry and Molecular Pharmacology Senior Vice President and Vice Dean for Science NYU Langone Health
David E. Fisher, MD, PhD Chair, Department of Dermatology, Massachusetts General Hospital Director, Melanoma Program MGH Cancer Center Director, Cutaneous Biology Research Center, MGH Edward Wigglesworth Professor of Dermatology, Harvard Medical School
Robert E. Kingston, PhD Chief Academic Officer, Massachusetts General Hospital Professor of Genetics, Harvard Medical School
David N. Louis, MD Associate Chief of Pathology for Research, Massachusetts General Hospital Professor of Pathology, Harvard Medical School Atul K. Bhan, MBBS, MD, Endowed Chair in Experimental Pathology
M. Celeste Simon, PhD Scientific Director, Abramson Family Cancer Research Institute Arthur H. Rubenstein, MBBCh Professor, Department of Cell and Developmental Biology University of Pennsylvania Perelman School of Medicine
External Advisory Board 2024
Robert E. Kingston, PhD Chief Academic Officer, Massachusetts General Hospital Professor of Genetics, Harvard Medical School
David N. Louis, MD Associate Chief of Pathology for Research, Massachusetts General Hospital Professor of Pathology, Harvard Medical School Atul K. Bhan, MBBS, MD, Endowed Chair in Experimental Pathology
David E. Fisher, MD, PhD Chair, Department of Dermatology, Massachusetts General Hospital Director, Melanoma Program MGH Cancer Center Director, Cutaneous Biology Research Center, MGH Edward Wigglesworth Professor of Dermatology, Harvard Medical School
M. Celeste Simon, PhD Scientific Director, Abramson Family Cancer Research Institute Arthur H. Rubenstein, MBBCh Professor, Department of Cell and Developmental Biology University of Pennsylvania Perelman School of Medicine
Arlene Sharpe, MD, PhD Chair, Department of Immunology Kolokotrones University Professor, Harvard Medical School
Matt Vander Heiden, PhD Director, Koch Institute for Integrative Cancer Research Lester Wolfe Professor of Molecular Biology, MIT
The newly named Krantz Family Center for Cancer Research will empower Mass General Cancer Center researchers to tackle the major unsolved challenges in oncology.
